Christos Fountzilas, MD, FACP, discusses findings from a study of molecular characterization in patients with colorectal cancer treated with cetuximab, an EGFR inhibitor, and pembrolizumab, a PD-1 inhibitor.
Christos Fountzilas, MD, FACP
Advertisement
Articles by Christos Fountzilas, MD, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
2
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
3
Aglatimagene Besadenovec Plus EBRT Improves Prostate Cancer-Specific DFS
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5